Our Founder Dr. Simon Ward and his Team
Skin+CELL was developed by a specialist research team working with Dr. Simon Ward, Chief Executive Officer and co-founder of Incanthera plc, a UK-based company specialising in innovative technologies in dermatology and oncology.
With over 30 years of senior experience in both academia and business, Dr. Ward has a strong background in pharmaceutical development and commercialisation. Together with his team of scientists at Incanthera plc, led by Dr Kevin Hammond and Dr Neil Kilcullen, and researchers from the Institute of Cancer Therapeutics (ICT), from which Incanthera originated, and the Centre for Skin Sciences at the University of Bradford, the key patented technologies delivering bioactive ingredients for health and longevity into the skin and skin cell mitochondria were developed into the Skin+CELL range.
Prior to founding Incanthera, Dr. Ward served as the CEO of Molecular SkinCare Limited, a company focused on developing novel dermatology products for the prevention and management of skin diseases. He also held the position of Chief Scientific Officer at York Pharma plc, where he was responsible for bringing innovative dermatology products to market. Additionally, Dr. Ward has served as chairman of the South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.
Dr. Ward holds a Joint Honours Degree in Pharmacology and Toxicology from the University of London’s School of Pharmacy and was awarded a DPhil from the Department of Human Anatomy at Oxford University under a Glaxo Group Research Studentship. He has spent much of his career researching and teaching embryology, oncology and dermatology at the University Medical Schools of Oxford and Sheffield in the United Kingdom.
Meet Dr. Simon Ward
Dr Kevin Hammond
Dr. Hammond brings over 30 years of global experience with leading pharmaceutical, FMCG, and healthcare companies, including GSK, Unilever, Reckitt Benckiser, and PZ Cussons, driving innovation, licensing, and strategic partnerships across Europe, the Americas, and Asia. A recognised industry expert, former editorial board member of the International Journal of Cosmetic Science, and seasoned lecturer, he has delivered and licensed patented technologies in skincare — including the award-winning Ceradan Advanced for eczema-prone skin. Dr. Hammond has secured high-value deals with major multinationals and continues to champion innovations that improve quality of life, generate investor returns, and create new market opportunities.
Dr Neil Kilcullen
Dr. Kilcullen brings over 30 years’ industry experience, including senior roles at Unilever, EC De Witt, and Reckitt Benckiser, with hands-on expertise spanning concept creation, formulation, scale-up, and production. He has led product development across multiple categories and crafted formulations for leading skincare brands including Witch, T-Zone, Clearasil, and E45. Having collaborated with Dr. Hammond at several companies, he now reunites with him to drive the formulation and development of groundbreaking new innovations.
Dr Kevin Hammond
Dr. Hammond brings over 30 years of global experience with leading pharmaceutical, FMCG, and healthcare companies, including GSK, Unilever, Reckitt Benckiser, and PZ Cussons, driving innovation, licensing, and strategic partnerships across Europe, the Americas, and Asia. A recognised industry expert, former editorial board member of the International Journal of Cosmetic Science, and seasoned lecturer, he has delivered and licensed patented technologies in skincare — including the award-winning Ceradan Advanced for eczema-prone skin. Dr. Hammond has secured high-value deals with major multinationals and continues to champion innovations that improve quality of life, generate investor returns, and create new market opportunities.
Dr Neil Kilcullen
Dr. Kilcullen brings over 30 years’ industry experience, including senior roles at Unilever, EC De Witt, and Reckitt Benckiser, with hands-on expertise spanning concept creation, formulation, scale-up, and production. He has led product development across multiple categories and crafted formulations for leading skincare brands including Witch, T-Zone, Clearasil, and E45. Having collaborated with Dr. Hammond at several companies, he now reunites with him to drive the formulation and development of groundbreaking new innovations.
Incanthera plc is listed on the Aquis Stock Exchange under the ticker symbol INC.
The company originated from the Institute of Cancer Therapeutics at the University of Bradford and focuses on developing innovative solutions to current clinical and commercially relevant unmet needs in dermatology and oncology.